$ARQT

Jefferies reiterated a Buy rating and $39.00 price target for Arcutis Biotherapeutics (ARQT) due to Zoryve's prescription growth, estimating Q3 2026 sales of $143M. The stock trades at $24.17, below analyst targets. Zoryve's Q3 growth moderated to 8-9% from 13-14% in Q2, with strong margins. Jefferies expects Q4 sales to improve seasonally and forecasts 2026 sales of $525-540M. ARQT reported Q2 2026 revenue of $129.9M, up 59% YoY, and turned profitable.

Curran Terrie sold 38,200 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $25.03 ($0.96M total) across 2 trades on 2026-08-27.

Burnett Patrick (See Remarks) sold 15,000 shares of Arcutis Biotherapeutics, Inc. (ARQT) at an average of $26.33 ($26.08–$26.52, $0.39M total) across 2 trades over 2026-08-11 to 2026-08-12.

Mizuho updated its U.S. healthcare “Top Picks” list for 2026, citing seven companies across biotech, medical devices, and healthcare services. Highlights include Eyepoint Pharmaceuticals (Duravyu Phase 3 data expected Aug 2026), Vaxcyte (PCV Phase 3 OPUS-1 data in Q4 2026), Erasca (raised about $632.5M in an offering), and Arcutis (Zoryve guidance $480M-$495M for 2026).

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. arqt-20260715 FALSE 0001787306 0001787306 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________ FORM 8-K ___________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d)

Mizuho, via Investing.com, highlighted seven U.S. healthcare stocks for growth, citing clinical catalysts and operational updates. Price targets and ratings include EYPT $36, PCVX $163, ERAS $26, ARQT $35, LNTH $115, EHC $134, and SOLV $100. Key items include EYPT Phase 3 data in Aug 2026, PCVX Phase 3 in 4Q 2026, and LNTH PDUFA mid-Aug 2026.

Arcutis Biotherapeutics (ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for infants with mild to moderate atopic dermatitis aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027, supported by INTEGUMENT-INFANT Phase 2 and Phase 1 PK data. ARQT shares closed at $27.67.

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

Arcutis Biotherapeutics (Nasdaq: ARQT) said it granted 61,000 restricted stock units to 9 newly hired employees under its 2022 Inducement Plan, approved by the Compensation Committee. The RSUs were granted July 1, 2026 and vest over four years (25% annually) if employment continues, per Nasdaq Rule 5635(c)(4).